Terremoto Biosciences, a pioneer in covalent drug discovery and development, has successfully raised an impressive $175 million in its latest funding round. This financing, supported by prominent investors OrbiMed and Third Rock Ventures, will catalyze Terremoto's mission to innovate highly targeted, small molecule medicines that feature unmatched selectivity, potency, and efficacy. Leveraging the groundbreaking science of lysine-based covalency, the company seeks to create both best-in-class therapies for recognized drug targets and first-in-class medicines for previously undruggable conditions. With a team that includes many of the original contributors to this emergent field, Terremoto is poised to expand the horizon of drug discovery, tackling a wide array of diseases and broadening the pool of tractable targets. The infusion of capital will accelerate ongoing research and development efforts, enabling Terremoto to advance its robust pipeline of therapies designed to deliver superior therapeutic benefits to patients worldwide. As the demand for innovative and effective medications continues to grow, Terremoto's cutting-edge approach aims to redefine treatment landscapes while improving outcomes for those suffering from complex diseases. With this latest funding round, Terremoto Biosciences is not only investing in its future but also in the future of medicine itself. For more information on their groundbreaking work, visit www.terremotobio.com.
Terremoto Biosciences Secures $175 Million Funding for Breakthrough Drug Development Innovations
Get the full Terremoto Biosciences company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
P2 Science, Inc.
We are the New Green Chemistry Company with a mission to de-carbonize the chemical industry, using the power of green chemistry.
$23.0M Unknown
today
Backoffice Solutions, Inc.
Backoffice Solutions, Inc. (BSI) is a domestic corporation that offers back-office support to micro, small and medium Enterprises, sole proprietors or self-employed individuals. Registered under the Securities Exchange Commission (SEC) since 14 August 2012. Our company has worked with varied private sector companies and organizations, allowing us to develop expertise in the following sectors: * Online Market Place * Restaurants and Food Chains * Forwarding Business * Travel & Tours * Advertising & Marketing * Domestic Manpower Agency * Hotels, Resorts & Tourism * International Manning Agency * Training School * Ship Management
$163.5K Unknown
today
Evolve Neuro
Transforming ADHD diagnosis with proprietary neuroscience and AI. Our 10-minute EEG-based assessment unlocks scalable, evidence-backed insights — targeting a global market underserved by outdated, subjective methods.
$1.9M Seed
today
Phytolon
Phytolon offers natural food colors, uniquely positioned to comply with the consumers needs for healthy food, and with the industry requirements for cost-efficiency and high quality. Phytolon leverages a novel and sustainable fermentation-based technology by which betalain natural colors are produced in baker's yeast.
$23.6M Series b
today
OZOREON
Our (H)unit® is a robust offgrid adapted ozone generator, built to last. With proprietary components and design it can withstand any humidity in the feed gas. We offer it as a stand-alone product or included in an automation cabinet. As an add-on we also provide a customized offgrid power-supply kit. The beneficial combination of ozone and high humidity is a known fact in the industry, and has been documented for 80+ years. The synergistic effects causes higher oxidizing and disinfecting properties than a dry ozone treatment does. And OZOREON has the technology for it.
$320.0K Unknown
today